Barinthus Biotherapeutics (BRNS) Operating Expenses (2020 - 2026)

Over the trailing twelve months to Jun 30, 2026, Barinthus Biotherapeutics reported Operating Expenses of $43.94 million, down 52.4% year-over-year; for FY2025, it was $71.06 million, down 15.5% from FY2024.

• Operating Expenses carries a five-year compound annual growth rate of 23.4% (FY2020 to FY2025).
• Going back by year, Operating Expenses was $84.12 million in FY2024 (-0.7%), $84.72 million in FY2023 (+73.8%), $48.74 million in FY2022 (+7.2%) and $45.49 million in FY2021 (+82.9%).
• The five-year range for quarterly Operating Expenses is -$1.07 million (Q3 2022) to $31.55 million (Q4 2022).
• Year-over-year, Operating Expenses has declined for four consecutive quarters, with an average decline of 12.0% over the last eight quarters.
• The fastest year-over-year change in Operating Expenses over five years came in Q2 2023 (growth of 596.7%), and the weakest in Q2 2022 (a decline of 77.3%).
• Business Quant data shows BRNS's Operating Expenses at $6.12 million (Q1 2026), $11.57 million (Q4 2025) and $15.22 million (Q3 2025) in the three quarters before Q2 2026.